Abstract: . . .  profiling. Am H Hypertens 1999; 12: 1077-83. 34. Lim PO, Dow E, Grennan G, et al. High prevalance of primary aldostero- nism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-9. 35. Gordon RD, Stowasser M, Tunny TJ, et al. High incidence of primary aldosteronism in 199 patients referred with hypertension . Clin Exp Pharmacol Physiol 1994; 21: 315-8. 36. Galley BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism with- out discontinuing hypertensive medications: the plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705. 37. Benchetrit S, Bernheim J, Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension . Isr Med Assoc J 2002; 1:17-20 38. Safian RD, Textor S. Renal-artery stenosis. NEJM 2001; 344: 431-42. 39. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolac- tone in the treatment of patients with refractory hypertension . Am J Hypertens 2002; 15: 333-9.  . . .
. . .  TJ, et al. High incidence of primary aldosteronism in 199 patients referred with hypertension . Clin Exp Pharmacol Physiol 1994; 21: 315-8. 36. Galley BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism with- out discontinuing hypertensive medications: the plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705. 37. Benchetrit S, Bernheim J, Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension . Isr Med Assoc J 2002; 1:17-20 38. Safian RD, Textor S. Renal-artery stenosis. NEJM 2001; 344: 431-42. 39. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolac- tone in the treatment of patients with refractory hypertension . Am J Hypertens 2002; 15: 333-9.  . . .
--2932,2,733,2010,14659